CTL019 clinical trials

Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients

This study looks at a new treatment called tisagenlecleucel for children and young adults (ages 1-25) with a type of blood cancer called B-cell acute lymphoblastic leukemia (B-ALL). It aims to see how well it works and if it's safe after standard first-line treatment.